Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06349759 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances
A Phase 3 study, sponsored by Ocuphire Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
NCT06349759 is a Phase 3 study that has completed, run by Ocuphire Pharma. The registered enrollment target is 200 participants.
The verdict
NCT06349759, a Phase 3 study, has completed, sponsored by Ocuphire Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
Study Summary
Safety and efficacy of 0.75% Phentolamine Ophthalmic Solution to improve mesopic low contrast visual acuity in subjects with post-refractive surgery visual disturbances.
Interventions
- DRUG Placebo
- DRUG phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2026-02-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06349759
The ClinicalTrials.gov registry entry for NCT06349759 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocuphire Pharma, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06349759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06349759 about?
NCT06349759 is a clinical study titled "Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances". Safety and efficacy of 0.75% Phentolamine Ophthalmic Solution to improve mesopic low contrast visual acuity in subjects with post-refractive surgery visual disturbances.
What is the current status of trial NCT06349759?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2024-04-01. Estimated completion is 2026-02-19.
What interventions are being tested in trial NCT06349759?
The interventions under investigation include: Placebo (DRUG), phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist (DRUG).
Who is sponsoring clinical trial NCT06349759?
This trial is sponsored by Ocuphire Pharma, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.